Successful Treatment of Delayed Localized Necrotizing Inflammatory Myositis After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine: A Case Report

Reported adverse reactions to the mRNA-1273 vaccine (Spikevax, Moderna Inc) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from mild, local delayed cutaneous reactions to rarer, more serious reactions such as myocarditis. Here, we describe the presentation and successful...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jennifer Chen, Siglin, Jonathan, Marshall, Michael S, Stemmer-Rachamimov, Anat, Bloom, Seth M, Blumenthal, Kimberly G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Novel Id Cases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578160/
https://www.ncbi.nlm.nih.gov/pubmed/36267257
http://dx.doi.org/10.1093/ofid/ofac499
Descripción
Sumario:Reported adverse reactions to the mRNA-1273 vaccine (Spikevax, Moderna Inc) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from mild, local delayed cutaneous reactions to rarer, more serious reactions such as myocarditis. Here, we describe the presentation and successful treatment of delayed, localized necrotizing inflammatory myositis following a third dose of the mRNA-1273 SARS-CoV-2 vaccine. To our knowledge, this is the first report of biopsy-confirmed, delayed inflammatory myositis after administration of an mRNA-1273 SARS-CoV-2 vaccine booster.

Ejemplares similares